



Immune Responses to Influenza Virus Antigens

Guest Editor:

Dr. Lynda Coughlan

Department of Microbiology,
Icahn School of Medicine at
Mount Sinai, New York, NY 10029,
USA

Deadline for manuscript
submissions:

closed (15 April 2021)

Message from the Guest Editor

The successful development of a universal influenza virus vaccine, which provides broad and durable protection, is a long-standing goal in the field.

The sub-optimal performance of traditional influenza vaccines has paved the way for the development of next-generation universal influenza virus vaccines using structurally stabilized or chimeric antigens, in the form of recombinant protein, viral vectors or nanoparticle-based platforms.

In this special issue, we encourage the submission of articles which present advances in our understanding of human immune responses to natural infection or immunization, studies which evaluate the immunogenicity and efficacy of novel universal influenza vaccines in animals or in clinical trials, as well as efforts to increase our understanding of the longevity of immunity directed towards cross-reactive epitopes.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College Roosevelt, 4331 CB Middelburg, The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)